IVD (in vitro diagnostics) market settles down to steady but modest growth after the roller-coaster ride of the last decade
This article was originally published in Clinica
Executive Summary
The in vitro diagnostics (IVDs) market worldwide is predicted to enjoy a modest 5% annual rise over the next five years, having weathered severe setbacks in 1996, when the worldwide market actually declined by 2%. This drop was the more surprising as it followed sales growth in double digits during the 1980s and early 1990s, according to information compiled by Theta Reports.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.